Medioresinol has been deciphered as a novel PGC-1α activator, and in brain microvascular endothelial cells, it enhances the interaction of PGC-1α with PPARα, resulting in an escalation in GOT1 and PAH expressions, causing a reduction in the build-up of phenylalanine triggered by ischemia, depletion of mitochondrial ROS, and ultimately prophylaxis of pyroptosis of BMVECs, blood brain barrier disruption, and ischemic brain damage [42]. The gene discussed is PPARGC1A; the disease is pulmonary arterial hypertension.